Reducing Antimicrobial Resistance With Rapid Tests
Widespread implementation of rapid diagnostic tests is critical for decreasing antimicrobial resistance.
You may also be interested in...
FDA’s new website emphasizes CDRH’s responsibility for bringing antimicrobial susceptibility tests to market.
This week, we learned that the US FDA thinks Elon Musk’s Neuralink brain interface device isn’t ready for human trials. Additionally, J&J cut about 300 medtech jobs, Stryker launched a knee implant, and Active Implants’ meniscus replacement device made it to the FDA’s advisory panel calendar.
The US needs a comprehensive plan to meet the country's testing needs in the earliest stages of an infectious disease crisis, according to a paper posted by the John Hopkins Center for Health Security. The authors of the paper say government and industry collaboration is essential in creating such a plan and urge both sectors to act now.